Xanodyne Pharmaceuticals

xanodyne pharmaceuticals, inc., founded in 2001, is an integrated specialty pharmaceutical company with both development and commercial capabilities focused on women's healthcare and pain management. we market a portfolio of revenue generating products consisting of prescription pharmaceuticals and a line of prenatal vitamins, and we are advancing a late stage pipeline of product candidates targeted at significant potential markets in xanodyne's focus areas. we are developing: zipsor™ for the treatment of mild to moderate acute pain for which we have received an approvable letter from the u.s. food & drug administration (fda); xp12b for the treatment of menorrhagia (heavy menstrual bleeding) has recently received top line phase 3 clinical data and nda filing is being completed; and xp20b for the treatment of mild to moderate pain for which a phase 3 trial has been completed in the u.s.